PRODUCTS

Catalog Number:RP0034
Recombinant Human Vitronectin (C-6His)
Copy Product Information

Size:

500 μg

1000 μg

Price:

$300.00

$440.00

Delivery: Order now, ship in 3 days

Product Details
Product Name Recombinant Human Vitronectin (C-6His) Accesstion Number AAH05046.1
Alternative Names Vitronectin; VN; S-Protein; Serum-Spreading Factor; V75; VTN
Description Recombinant Human Vitronectin is produced by our Mammalian expression system and the target gene encoding Asp20-Leu478 is expressed with a 6His tag at the C-terminus.
Calculated Molecular Weight Mol Mass:53.35 KDa; APMol Mass:60-80 KDa, reducing conditions Formulation Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
Endotoxin < 1 EU/µg as determined by LAL test. Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity N/A
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Background Human Vitronectin/VTN is a cell adhesion and spreading factor. It can be found in the blood and the extracellular matrix (ECM). Vitronectin interacts with glycosaminoglycans and proteoglycans. The multimeric Vitronectin can efficiently bind to and incorporate into the ECM; Vitronectin can support cell adhesion through binding to various integrins and other proteoglycans. Vitronectin can be recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecular. It can as a inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway. Vitronectin contains an endogenous cleavage site, plus cleavage sites for elastase, thrombin, and plasmin.
  • Greater than 95% as determined by reducing SDS-PAGE. (QC verified)